newsfilter
← Latest News
GlobeNewswire·

Surface Oncology Announces Promising SRF388 Monotherapy Data in Non-Small Cell Lung Cancer (NSCLC), Opening Second Stage of Monotherapy Trial and NSCLC Pembrolizumab Combination Cohort

– Two confirmed partial responses to SFR388 monotherapy treatment in squamous NSCLC; third patient with NSCLC experienced durable disease stabilization for over a year – – Company focusing resources on advancement